查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954193

抗藥性金黃色葡萄球菌(MRSA) 市場分析及預測（至 2035 年）：按類型、產品、服務、技術、應用、設備、最終用戶、流程和解決方案分類

Methicillin-Resistant Staphylococcus Aureus (MRSA) Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Device, End User, Process, Solutions
出版日期: | 出版商: Global Insight Services | 英文 329 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計抗藥性金黃色葡萄球菌(MRSA) 市場規模將從 2024 年的 51 億美元成長至 2034 年的 76 億美元，複合年成長率約為 4.1%。 MRSA 市場涵蓋 MRSA感染疾病的診斷工具、治療方法和預防措施的開發和分銷。市場成長的促進因素包括 MRSA 感染率的上升、快速診斷技術的進步以及對有效抗藥性金黃色葡萄球菌治療的需求。主要趨勢包括新型抗生素的出現、疫苗的研發以及醫療機構感染控制通訊協定的加強。

由於診斷技術的進步和治療方法的創新，抗藥性金黃色葡萄球菌(MRSA) 市場預計將迎來顯著成長。診斷領域，尤其是快速診斷檢測，表現良好，這主要得益於對及時準確檢測 MRSA 的需求。分子診斷工具因其更高的靈敏度和特異性而日益重要，在 MRSA 疫情控制中發揮至關重要的作用。治療領域也緊隨其後，新型抗生素和聯合治療正成為 MRSA感染疾病控制的關鍵組成部分。隨著傳統治療方法面臨抗藥性挑戰，對新型抗生素的需求不斷成長。包括衛生用品和消毒解決方案在內的感染控制領域也呈現強勁成長，凸顯了預防措施的重要性。此外，醫院感染控制通訊協定也擴大採用先進的滅菌和消毒技術。旨在開發創新解決方案以應對日益嚴重的 MRSA 威脅的策略聯盟和研究舉措進一步鞏固了市場地位。

市場區隔
類型 院內獲得性抗甲氧西林金黃色葡萄球菌（MRSA）、社區型抗甲氧西林金黃色葡萄球菌（MRSA）
產品 抗生素、消毒劑、防腐劑和創傷護理產品
服務 診斷、諮詢和治療服務
科技 聚合酵素鏈鎖反應（PCR）、微陣列、免疫檢測
適用的 醫院、診所、居家醫療機構、實驗室
醫療設備 診斷和治療設備
最終用戶 醫療保健機構、研究機構和製藥公司
流程 篩檢和監測
解決方案 感染控制、抗菌藥物管理計劃

抗藥性金黃色葡萄球菌(MRSA) 市場正經歷市場佔有率、定價策略和產品創新的動態變化。主要企業正致力於開發新型治療方法以應對日益嚴重的抗藥性問題。這造就了競爭激烈的市場格局，定價策略對於維持市場地位至關重要。各公司正迅速推出承諾提高療效並減少副作用的新產品。策略重點在於拓展產品系列，以滿足未被滿足的需求並改善患者預後。地域擴張和策略聯盟對於獲取市場佔有率也至關重要。 MRSA 市場的競爭基準研究顯示，該市場格局高度分散，眾多公司競相爭奪主導。監管影響顯著，嚴格的指導方針規範新治療方法的開發和核准。該市場的特點是研發活動十分活躍，各公司大力投資創新以獲得競爭優勢。北美和歐洲在法規結構處於主導地位，影響全球市場動態。對抗菌藥物管理和降低抗藥性策略的重視正在推動市場發展，帶來成長機會和創新。

主要趨勢和促進因素：

由於感染率上升和人們對抗生素抗藥性的認知不斷提高，耐甲氧西林金黃色葡萄球菌（MRSA）市場正在成長。關鍵趨勢包括新型抗生素和快速診斷工具的研發，這些對於有效控制MRSA感染疾病至關重要。此外，嚴格的監管指南和不斷加強的病患安全措施也提高了醫療機構感染預防措施的重要性。市場促進因素包括MRSA感染疾病在全球日益普遍，需要有效的治療方案。現有抗生素的局限性以及對更具針對性治療方法的需求進一步推動了對先進治療方法的需求。此外，政府和私營部門對研發的投資正在加速該領域的創新。在MRSA負擔沉重的新興市場，擴大醫療基礎設施存在著機會。專注於提供價格合理且易於獲得的治療方案的公司有望佔據可觀的市場佔有率。此外，製藥公司與研究機構合作開發下一代抗生素和診斷解決方案，預計將推動MRSA市場的持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 本院內感染抗甲氧西林金黃色葡萄球菌
    • 社區型抗甲氧西林金黃色葡萄球菌
  • 市場規模及預測：依產品分類
    • 抗生素
    • 抗菌劑
    • 消毒劑
    • 創傷護理產品
  • 市場規模及預測：依服務分類
    • 診斷服務
    • 諮詢服務
    • 治療服務
  • 市場規模及預測：依技術分類
    • 聚合酵素鏈鎖反應（PCR）
    • 微陣列
    • 免疫檢測
  • 市場規模及預測：依應用領域分類
    • 醫院
    • 診所
    • 居家醫療環境
    • 研究所
  • 市場規模及預測：依設備分類
    • 診斷設備
    • 治療設備
  • 市場規模及預測：依最終用戶分類
    • 醫療保健提供者
    • 研究所
    • 製藥公司
  • 市場規模及預測：依製程分類
    • 篩檢
    • 監測
  • 市場規模及預測：按解決方案分類
    • 感染控制
    • 抗菌藥物管理計劃

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Melinta Therapeutics
  • Paratek Pharmaceuticals
  • Nabriva Therapeutics
  • Cempra
  • Achaogen
  • Motif Bio
  • Basilea Pharmaceutica
  • Tetraphase Pharmaceuticals
  • Iterum Therapeutics
  • Aridis Pharmaceuticals
  • Debiopharm Group
  • Spero Therapeutics
  • Enanta Pharmaceuticals
  • Venatorx Pharmaceuticals
  • Forge Therapeutics
  • Wockhardt
  • Polyphor
  • Shionogi
  • Biocidium
  • Micu Rx Pharmaceuticals

第9章：關於我們

簡介目錄
Product Code: GIS26118

Methicillin-Resistant Staphylococcus Aureus (MRSA) Market is anticipated to expand from $5.1 billion in 2024 to $7.6 billion by 2034, growing at a CAGR of approximately 4.1%. The Methicillin-Resistant Staphylococcus Aureus (MRSA) Market encompasses the development and distribution of diagnostic tools, treatments, and preventive measures for MRSA infections. This market is driven by the increasing prevalence of MRSA, advancements in rapid diagnostic technologies, and the need for effective antibiotic therapies. Key trends include the rise of novel antibiotics, vaccine development, and enhanced infection control protocols in healthcare settings.

The Methicillin-Resistant Staphylococcus Aureus (MRSA) Market is poised for significant growth, propelled by advancements in diagnostic technologies and therapeutic innovations. The diagnostic segment, particularly rapid diagnostic tests, leads in performance, driven by the need for timely and accurate detection of MRSA. Molecular diagnostic tools are gaining prominence, offering enhanced sensitivity and specificity, which are critical in managing MRSA outbreaks. The therapeutic segment follows closely, with novel antibiotics and combination therapies emerging as vital components in combating MRSA infections. The demand for newer antibiotics is rising, as traditional treatments face resistance challenges. The infection control segment, encompassing hygiene products and decontamination solutions, is also witnessing robust growth, underscoring the importance of preventive measures. Furthermore, hospital-acquired infection control protocols are increasingly incorporating advanced sterilization and disinfection technologies. The market is further bolstered by strategic collaborations and research initiatives aimed at developing innovative solutions to address the growing MRSA threat.

Market Segmentation
TypeHospital-Acquired MRSA, Community-Acquired MRSA
ProductAntibiotics, Antiseptics, Disinfectants, Wound Care Products
ServicesDiagnostic Services, Consultation Services, Treatment Services
TechnologyPolymerase Chain Reaction (PCR), Microarray, Immunoassay
ApplicationHospitals, Clinics, Home Care Settings, Research Laboratories
DeviceDiagnostic Devices, Therapeutic Devices
End UserHealthcare Providers, Research Institutes, Pharmaceutical Companies
ProcessScreening, Surveillance
SolutionsInfection Control, Antimicrobial Stewardship

The Methicillin-Resistant Staphylococcus Aureus (MRSA) market is witnessing a dynamic shift in market share, pricing strategies, and product innovation. Key players are focusing on developing novel treatments to address the growing resistance issues. This has led to a competitive landscape where pricing strategies are crucial for maintaining market presence. Companies are launching new products that promise enhanced efficacy and reduced side effects. The strategic emphasis is on expanding product portfolios to cater to unmet medical needs and improve patient outcomes. Geographical expansion and strategic partnerships are also pivotal in capturing market share. Competition benchmarking in the MRSA market reveals a highly fragmented landscape with numerous players vying for dominance. Regulatory influences play a significant role, as stringent guidelines shape the development and approval of new treatments. The market is characterized by intense R&D activities, with firms investing heavily in innovation to gain a competitive edge. North America and Europe lead in regulatory frameworks, impacting global market dynamics. The focus on antibiotic stewardship and resistance mitigation strategies is driving market evolution, presenting opportunities for growth and innovation.

Geographical Overview:

The Methicillin-Resistant Staphylococcus Aureus (MRSA) market is witnessing varied growth patterns across different regions. North America remains a dominant player, benefiting from advanced healthcare infrastructure and significant R&D investments. The region's proactive approach towards infection control and robust healthcare policies further bolsters the market's expansion. Europe is experiencing steady growth, driven by heightened awareness and stringent healthcare regulations. The region's commitment to combating antibiotic resistance is fostering a conducive environment for MRSA market development. In Asia Pacific, burgeoning healthcare infrastructure and rising public health initiatives are propelling market growth. Countries like India and China are emerging as pivotal players, investing heavily in healthcare advancements. Latin America shows promising potential, with increased focus on healthcare improvements and infection control measures. The Middle East & Africa are gradually recognizing the importance of addressing MRSA, with countries in these regions beginning to invest in healthcare solutions to combat antibiotic-resistant infections.

The MRSA market is increasingly influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, reliance on imported raw materials for antibiotics faces tariff-induced cost pressures, prompting strategic investments in local pharmaceutical R&D. China's focus on strengthening its domestic healthcare infrastructure is accelerated by trade tensions, fostering innovation in MRSA treatments. Taiwan's robust biopharmaceutical sector remains crucial but is vulnerable to geopolitical volatility. The global MRSA market is expanding, driven by rising infection rates and healthcare demands. By 2035, market evolution will hinge on supply chain resilience, regional collaborations, and technological advancements. Additionally, Middle East conflicts may indirectly affect pharmaceutical supply chains by influencing energy prices, thereby impacting production and distribution costs globally.

Key Trends and Drivers:

The MRSA market is experiencing growth due to rising infection rates and increased awareness of antibiotic resistance. Key trends include the development of novel antibiotics and rapid diagnostic tools, which are essential in managing MRSA infections effectively. Additionally, there is a growing emphasis on infection prevention measures in healthcare settings, driven by stringent regulatory guidelines and patient safety initiatives. Drivers of the market include the increasing prevalence of MRSA infections globally, which necessitates effective treatment solutions. The demand for advanced therapeutics is further fueled by the limitations of existing antibiotics and the need for more targeted therapies. Furthermore, government and private sector investments in research and development are accelerating innovation in this field. Opportunities lie in the expansion of healthcare infrastructure in emerging markets, where the burden of MRSA is significant. Companies focusing on affordable and accessible treatment options can capture substantial market share. Additionally, partnerships between pharmaceutical companies and research institutions are fostering the development of next-generation antibiotics and diagnostic solutions, positioning the MRSA market for sustained growth.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Hospital-Acquired MRSA
    • 4.1.2 Community-Acquired MRSA
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Antibiotics
    • 4.2.2 Antiseptics
    • 4.2.3 Disinfectants
    • 4.2.4 Wound Care Products
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Diagnostic Services
    • 4.3.2 Consultation Services
    • 4.3.3 Treatment Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Polymerase Chain Reaction (PCR)
    • 4.4.2 Microarray
    • 4.4.3 Immunoassay
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Home Care Settings
    • 4.5.4 Research Laboratories
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 Diagnostic Devices
    • 4.6.2 Therapeutic Devices
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Healthcare Providers
    • 4.7.2 Research Institutes
    • 4.7.3 Pharmaceutical Companies
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Screening
    • 4.8.2 Surveillance
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Infection Control
    • 4.9.2 Antimicrobial Stewardship

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Device
      • 5.2.1.7 End User
      • 5.2.1.8 Process
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Device
      • 5.2.2.7 End User
      • 5.2.2.8 Process
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Device
      • 5.2.3.7 End User
      • 5.2.3.8 Process
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Device
      • 5.3.1.7 End User
      • 5.3.1.8 Process
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Device
      • 5.3.2.7 End User
      • 5.3.2.8 Process
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Device
      • 5.3.3.7 End User
      • 5.3.3.8 Process
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Device
      • 5.4.1.7 End User
      • 5.4.1.8 Process
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Device
      • 5.4.2.7 End User
      • 5.4.2.8 Process
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Device
      • 5.4.3.7 End User
      • 5.4.3.8 Process
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Device
      • 5.4.4.7 End User
      • 5.4.4.8 Process
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Device
      • 5.4.5.7 End User
      • 5.4.5.8 Process
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Device
      • 5.4.6.7 End User
      • 5.4.6.8 Process
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Device
      • 5.4.7.7 End User
      • 5.4.7.8 Process
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Device
      • 5.5.1.7 End User
      • 5.5.1.8 Process
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Device
      • 5.5.2.7 End User
      • 5.5.2.8 Process
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Device
      • 5.5.3.7 End User
      • 5.5.3.8 Process
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Device
      • 5.5.4.7 End User
      • 5.5.4.8 Process
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Device
      • 5.5.5.7 End User
      • 5.5.5.8 Process
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Device
      • 5.5.6.7 End User
      • 5.5.6.8 Process
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Device
      • 5.6.1.7 End User
      • 5.6.1.8 Process
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Device
      • 5.6.2.7 End User
      • 5.6.2.8 Process
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Device
      • 5.6.3.7 End User
      • 5.6.3.8 Process
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Device
      • 5.6.4.7 End User
      • 5.6.4.8 Process
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Device
      • 5.6.5.7 End User
      • 5.6.5.8 Process
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Melinta Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Paratek Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Nabriva Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cempra
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Achaogen
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Motif Bio
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Basilea Pharmaceutica
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Tetraphase Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Iterum Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Aridis Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Debiopharm Group
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Spero Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Enanta Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Venatorx Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Forge Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Wockhardt
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Polyphor
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Shionogi
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Biocidium
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Micu Rx Pharmaceuticals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us